Tempest Therapeutics, Inc.
No SEC Form 4 filings for $TPST in the last 30 days.
See all $TPST insider activity →Tempest Therapeutics (TPST) announced a private placement of 3.1M shares and warrants, raising $2.5M, with potential additional proceeds of $5M if warrants are exercised. Proceeds will be used for working capital. The offering is expected to close on September 14, 2026, subject to conditions.
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Principal Financial and Accounting Officer On August 18, 2026, Mr. Justin Trojanowski notified Tempest Therape
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. Item 8.01 Other Events. On August 17, 2026, Tempest Therapeutics, Inc. (the “Company”) called to order its
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TPST (Tempest Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent TPST coverage spans corporate actions, earnings and technology.
Modest capital infusion for working capital; limited immediate price impact.
Leadership change may affect financial reporting and capital raising execution.
The filing signals a governance vote is not yet approved and pushes the decision timeline to September 15, 2026.
Near-term sentiment is supported by improved losses and fresh pipeline milestones, but cash runway remains a key risk given $0.8M cash at June 30.
Near-term catalyst is TPST-4003 trial initiation timing (Q4 2026) plus TPST-2003 interim efficacy and safety signals, which can shift biotech risk pricing.
AlphAI scores every news story that mentions TPST with an AI model for sentiment and relevance, and aggregates insider trades from Tempest Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tempest Therapeutics (TPST) announced a private placement of 3.1M shares and warrants, raising $2.5M, with potential additional proceeds of $5M if warrants are exercised. Proceeds will be used for working capital. The offering is expected to close on September 14, 2026, subject to conditions.
1 min readTempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Principal Financial and Accounting Officer On August 18, 2026, Mr. Justin Trojanowski notified Tempest Therape
1 min readTempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. Item 8.01 Other Events. On August 17, 2026, Tempest Therapeutics, Inc. (the “Company”) called to order its
2 min readTempest Therapeutics (TPST) reported Q2 2026 net loss of $5.2M, or $0.34/share, versus $7.9M, or $2.07/share a year earlier. R&D fell to $1.8M and G&A to $3.4M. Cash was $0.8M at June 30. The company advanced TPST-4003 (CD19/BCMA via CD7 mRNA/LNP) with a Senlang collaboration and a China investigator trial starting Q4 2026, and cited interim TPST-2003 data. Shares were up in premarket.
6 min readTempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T,
6 min readTempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 13, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a purchase agreement (the “ Purchase Agreement ”) and a registration rights agreement (the “ Registration Rights Agreement
4 min readTempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001544227 0001544227 2026-07-27 2026-07-27 0001544227 us-gaap:CommonStockMember 2026-07-27 2026-07-27 0001544227 us-gaap:SeriesAPreferredStockMember 2026-07-27 2026-07-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pu
3 min readTempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 d107304dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 PRODUCT DEVELOPMENT AND INVESTIGATOR-INITIATED TRIAL (IIT) COLLABORATION AGREEMENT This Product Development and Investigator-Initiated Trial (IIT) Collaboration Agreement (this “Agreement”) is entered into as of July 17, 20
3 min readTempest Therapeutics (Nasdaq: TPST) said it will advance TPST-4003, its CD7-targeted mRNA/LNP in vivo CAR-T using a dual CD19/BCMA CAR, into a first investigator-initiated trial in nervous system autoimmune diseases. The study plans about 10 patients with MG and MS, with first dosing expected in Q4 2026 and initial data in H1 2027.
4 min readAngel Matthew (CEO and President) purchased 231,482 indirectly-held shares of Tempest Therapeutics, Inc. (TPST) at $2.16 ($0.50M total) on 2026-03-24.
2 min read
